Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease

Internal Medicine

Volumn 48, Issue 12, 2009, Pages 933-937

  Tsujikawa, Tomoyuki ^a,b   Andoh, Akira ^a,b   Inatomi, Osamu ^a,b   Bamba, Shigeki ^a,b   Nakahara, Tamio ^a,b   Sasaki, Masaya ^a,b   Saito, Haruyasu ^a,b   Fujiyama, Yoshihide ^a,b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

Author keywords

Alendronate; Bone mineral density; Crohn's disease; Steroid

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; FARNOQUINONE; MENATETRENONE; MERCAPTOPURINE; PREDNISOLONE; SALICYLIC ACID DERIVATIVE; STEROID;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERIC FEEDING; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MALE; OUTPATIENT; SIDE EFFECT; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ADULT; ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR NECK; GLUCOCORTICOIDS; HUMANS; LINEAR MODELS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; PREDNISOLONE; STEROIDS;

EID: 67650136615     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2005     Document Type: Article

References (25)

1. Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis 5: 200-211, 1999.
2. Kusunoki M, Möeslein G, Shoji Y, et al. Steroid complications in patients with ulcerative colitis. Dis Colon Rectum 35: 1003-1009, 1992.
3. Uchida K, Araki T, Toiyama Y, et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis Colon Rectum 49: 74-79, 2006.
4. Shinozaki M, Suzuki K, Sawada T, Tsuno N, Higuchi Y, Muto T. Steroid complications and surgery in intractable ulcerative colitis. J Gastroenterol 33: 196-200, 1998.
5. Kunisaki R, Chaki O, Taguchi T, Sugiyama T, Sugita A. Infliximab and the bone in Crohn's disease. Aliment Pharmacol Ther 21: 789-790, 2005.
6. Soen S, Tanaka Y. Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Mod Rheumatol 15: 163-168, 2005.
7. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 1363-1374, 1999.
8. Bailen LS. Bones and Crohn's: should we treat Crohn's disease patients with alendronate? Inflamm Bowel Dis 7: 175-176, 2001.
9. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 119: 639-646, 2000.
10. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 107: 1031-1039, 1994.
11. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 93: 1483-1490, 1998.
12. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4: 268-275, 1998.
13. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 28: 410-415, 1987.
14. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 43: 2500-2506, 1998.
15. Bischoff SC, Herrmann A, Göke M, Manns MP, von zur Mühlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 92: 1157-1163, 1997.
16. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol 94: 824-848, 1999.
17. Silvennoinen JA, Lehtola JK, Niemelä SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 31: 367-371, 1996.
18. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621-630, 2006.
19. Silvennoinen JA, Karttunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 37: 71-76, 1995.
20. Soen S. Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems. Clin Calcium 16: 1788-1796, 2006.
21. Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res 12: 431-438, 1997.
22. Hara K, Kobayashi M, Akiyama Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 31: 575-581, 2002.
23. Sasaki N, Kusano E, Takahashi H, et al. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 23: 41-47, 2005.
24. Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275: 27307-27310, 2000.
25. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 100: 2031-2035, 2005.